United States: U.S. Supreme Court Rules That Isolated Human Genes Are Unpatentable

Last Updated: June 14 2013
Article by Matthew Pavao, PhD, Richard G. Gervase and Ivor R. Elrifi, PhD

Summary

On June 13, 2013 in a much-anticipated decision, the U.S. Supreme Court in Association for Molecular Pathology v. Myriad Genetics, 569 U.S. __ (2013) unanimously held that claims for isolated DNA sequences are not patent eligible subject matter under 35 U.S.C. §101, but that claims for complementary DNA (cDNA) sequences are patent eligible subject matter.

The Supreme Court held that naturally occurring DNA is a product of nature and not patent eligible merely because it has been isolated. In contrast, cDNA is patent eligible because it has been synthetically created and is not naturally occurring.

Myriad History

The long-standing battle over gene patents began in May 2009 when The Association for Molecular Pathology along with other medical associations, researchers, and patients sued Myriad and the United States Patent and Trademark Office (USPTO) to challenge several patents claiming human genes.

The challenged patents, licensed to Myriad, claim isolated human BRCA1 and BRCA2 genes and methods of using these genes. More specifically, the Myriad claims fall into three main categories: 1) composition claims directed to cDNA and isolated DNA molecules coding for all or a portion of either of the BRCA genes; 2) method claims for comparing or analyzing DNA sequences to detect mutations in the BRCA genes; and 3) method claims for screening potential cancer therapeutics.

Mutations in the BRCA genes correlate with increased risk of breast and ovarian cancer. Thus, detection of BRCA mutations is critical to the diagnosis and treatment of these cancers. Myriad provides a diagnostic test, BRACAnalysis®, which detects the presence of a BRCA1 or BRCA2 gene mutation.

1. The District Court Decision

On March 29, 2010, Judge Sweet of the U.S. District Court of the Southern District of New York declared all of the contested claims invalid. Judge Sweet reasoned that "DNA's existence in an 'isolated' form alters neither this fundamental quality of DNA as exists in the body nor the information it encodes. Therefore, the patents at issue directed to 'isolated DNA' containing sequences found in nature are unsustainable as a matter of law and are deemed unpatentable under 35 U.S.C. §101." With respect to the method claims, Judge Sweet, applying In re Bilski 545 F.3d 943 (Fed. Cir. 2008), stated that a) methods of comparing DNA sequences are merely abstract mental processes and therefore not patent eligible; and b) drug screening claims are unpatentable as merely encompassing a "basic scientific principle". Myriad appealed to U.S. Court of Appeals for the Federal Circuit (CAFC).

2. The CAFC Decision

On July 29, 2011, in a first decision, a CAFC panel (Judges Lourie, Moore and Bryson) reversed the District Court in part and affirmed in part. Specifically, the CAFC disagreed with the District Court holding that isolated DNA sequences, cDNA sequences (exon-only DNA sequences artificially synthesized from mRNA templates) and methods of screening cancer therapeutics are patent eligible. However, the CAFC agreed with the District Court holding that method claims for comparing DNA sequences to detect mutations are not patent eligible under §101.

Regarding the patent-eligibility of isolated DNA molecules, the CAFC described the legal framework for patent eligible subject matter in Diamond v. Chakrabarty, 447 U.S. 303 (1980) and Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 U.S. 127 (1948), where the Supreme Court stated that the distinction made "between a product of nature and a human-made invention for the purposes of §101 turns on a change in the claimed composition's identity compared with what exists in nature."

In upholding the claims directed to isolated DNA, Judge Lourie reasoned that isolated DNA is "markedly different" because an isolated DNA molecule no longer contains the chemical bond that the naturally occurring gene has with other genetic materials. Judge Moore concurred in part but did not rely exclusively on Judge Lourie's conclusion that chemically breaking covalent bonds was sufficient to render isolated DNA patent eligible. Judge Bryson concurred in part and dissented in part concluding that isolated DNA is not patent eligible. He emphasized that the breaking of chemical bonds was not dispositive. Instead, he relied on the fact that the "nucleotide sequences of the claimed molecules are the same as nucleotide sequences found in naturally occurring human genes."1 The CAFC panel unanimously agreed that patent claims related to cDNA were patent eligible.2

On August 16, 2012, the same CAFC panel reaffirmed that isolated DNA molecules are patent eligible subject matter. The court maintained the position that isolated DNA is markedly different and has a distinctive chemical structure and identity as compared to naturally occurring DNA.3 The court agreed unanimously that cDNA may be patented, since cDNA is a form of DNA that never occurs naturally.4

3. The Supreme Court Decision

Justice Thomas delivered the unanimous opinion of the Court holding that extracted and isolated DNA from a human body is a product of nature and thus an exception to the statutory subject matter under 35 U.S.C. § 101. cDNA, in contrast, is synthetically created and thus not naturally occurring. Accordingly, cDNA is patent eligible. The ruling thus affirms in part and reverses in part the decision of the CAFC.

The Court noted that "patent protection strikes a delicate balance between creating 'incentives that lead to creation, innovation, and discovery' and 'imped[ing] the flow of information that might permit, indeed spur, invention'."

The Court acknowledged that "Myriad's principal contribution was uncovering the precise location and genetic sequence of the BRCA1 and BRCA2 genes." However, is the Court also acknowledged that it was undisputed that "Myriad did not create or alter either the genetic information encoded in the BRCA1 and BRCA2 genes or the genetic structure of the DNA. It found an important and useful gene, but groundbreaking, innovative, or even brilliant discovery does not by itself satisfy the §101 inquiry."

In addressing the CAFC's decision, the Court noted that the central dispute among the panel members was whether the act of isolating DNA – separating a specific gene or sequence of nucleotides from the rest of the chromosome – is an inventive act that entitles the individual who first isolates it to a patent. In that regard, the Court stated that the "Myriad claims are not saved by the fact that isolating DNA from the human genome severs the chemical bonds that bind gene molecules together. The claims are not expressed in terms of chemical composition, nor do they rely on the chemical changes resulting from the isolation of a particular DNA section. Instead, they focus on the genetic information encoded in the BRCA1 and BRCA2 genes." The Court went on to state that in this case "Myriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention."

In contrast, the Court held that "cDNA does not present the same obstacles to patentability as naturally occurring, isolated DNA." The Court stated the creation of a cDNA sequence from mRNA results in an exons-only molecule that is not naturally occurring. cDNA is not a product of nature so it is patent eligible under §101.

The Court was careful to note that the decision does not address method claims, hands-on new applications of knowledge about the BRCA1 and BRCA2 genes, or the patentability of DNA in which the order of naturally occurring nucleotide has been altered. With respect to altered DNA, the Court specifically stated that "scientific alteration of the genetic code presents a different inquiry, and we express no opinion about the application of §101 to such endeavors."

Justice Scalia provided a brief concurrence, where he did not join portions of the opinion regarding the underlying molecular biology.

Footnotes

1  On the method claims, the CAFC applying Bilski v. Kappos, 130 S.Ct. 3218 (2010) held that claims directed to methods of comparing or analyzing DNA sequences to detect mutations merely amount to "abstract mental process of comparing two nucleotide sequences" and therefore were not patent eligible. In contrast, the court held that the method claims directed to screening for potential cancer therapeutics by measuring changes in cell growth rates, included two transformative steps, which render them patent eligible.

2 Following the CAFC decision, The Association for Molecular Pathology petitioned for a writ of certiorari to the Supreme Court. On March 26, 2012, the Supreme Court vacated the decision and remanded the case to the Federal Circuit for reconsideration in view of the Supreme Court's decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S.Ct. 1289 (2012).

3 On the method claims, the court also reaffirmed that the method of screening drugs using genetically modified cells is patent eligible and unanimously supported its earlier decision that the methods of comparing DNA sequences to detect mutations is not patentable subject matter.

4 On September 25, 2012, the American Civil Liberties Union and the Public Patent Foundation requested certiorari to address the question "are human genes patentable?" and oral arguments were heard before the Supreme Court on April 15, 2013

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Matthew Pavao, PhD
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions